Abstract
Purpose: We hypothesized plasma CTGF concentration would be a biomarker for clinical AF. Methods: The study population consisted of consecutive 64 patients with minimal structural heart disease. They were divided into two groups; 1) SR (sinus rhythm, n=6), and 2) AF (n=58, chronic AF n=13, and paroxysmal AF n=45). The AF group was further divided into two subgroups with and without ARB or angiotensin converting enzyme inhibitor (ACEI). The clinical characteristics and plasma CTGF concentrations, which were evaluated by ELISA, were compared. Results: The plasma CTGF concentration in total population was 0.653±0.091 ng/mL and tended to be higher in AF group than SR group (SR vs. AF groups: 0.450±0.091 vs. 0.674±0.101 ng/mL, p=0.328). ARB/ACEI was administered in 33/58 AF patients (56.9%). Plasma CTGF concentration tended to be lower in the AF with ARB/ACE-I group than the AF without ARB/ACE-I group (AF+ARB/ACEI vs. AF-ARB/ACEI groups: 0.583±0.083 vs. 0.794±0.206 ng/mL, p=0.198). Conclusions: It might be speculated plasma CTGF concentration would be a novel biomarker for AF and this increase would be suppressed by ARB/ACEI in clinical patients with AF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
